Dr. Roboz on Advancements on the Horizon in AML

Gail Roboz, MD
Published: Friday, Aug 18, 2017



Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses advancements emerging on the horizon in acute myeloid leukemia (AML).

While agents have emerged and have been FDA approved in other hematologic malignancies, there are similar advancements finally occurred in the AML landscape, Roboz explains. There are several promising combination therapies that are building on standard chemotherapy backbones. For older patients, hypomethylating agents and low-dose cytarabine are regimens that are less likely to yield many complete remissions (CRs) or long-term outcomes.

However, they are being combined successfully with novel agents. Some of these potential combinations in early trials include CR rates of more than 60% at this point, which is much better than the 15% to 25% CR rate that we are used to.
 


Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses advancements emerging on the horizon in acute myeloid leukemia (AML).

While agents have emerged and have been FDA approved in other hematologic malignancies, there are similar advancements finally occurred in the AML landscape, Roboz explains. There are several promising combination therapies that are building on standard chemotherapy backbones. For older patients, hypomethylating agents and low-dose cytarabine are regimens that are less likely to yield many complete remissions (CRs) or long-term outcomes.

However, they are being combined successfully with novel agents. Some of these potential combinations in early trials include CR rates of more than 60% at this point, which is much better than the 15% to 25% CR rate that we are used to.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x